Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b mavrilimumab in moderate-to-severe rheumatoid arthritis
2011-005634-19Phase 2Completed
- Sponsor
- MedImmune
- Start
- Apr 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Mavrilimumab with Placebo (2 arms). Primary endpoints: Primary RA efficacy change at Week 12 and Primary RA efficacy change at Week 24. Started Apr 2012; status: completed.
02
Drugs
mavrilimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2011-005634-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005634-19.